IL155279A0 - Methods of treatment using wisp polypeptides - Google Patents

Methods of treatment using wisp polypeptides

Info

Publication number
IL155279A0
IL155279A0 IL15527901A IL15527901A IL155279A0 IL 155279 A0 IL155279 A0 IL 155279A0 IL 15527901 A IL15527901 A IL 15527901A IL 15527901 A IL15527901 A IL 15527901A IL 155279 A0 IL155279 A0 IL 155279A0
Authority
IL
Israel
Prior art keywords
treatment
administration
cartilage
injury
repair
Prior art date
Application number
IL15527901A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL155279A0 publication Critical patent/IL155279A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL15527901A 2000-10-16 2001-10-12 Methods of treatment using wisp polypeptides IL155279A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24122200P 2000-10-16 2000-10-16
PCT/US2001/032142 WO2002033085A2 (en) 2000-10-16 2001-10-12 Wisp polypeptides and therapeutical applications thereof

Publications (1)

Publication Number Publication Date
IL155279A0 true IL155279A0 (en) 2003-11-23

Family

ID=22909763

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15527901A IL155279A0 (en) 2000-10-16 2001-10-12 Methods of treatment using wisp polypeptides
IL155279A IL155279A (en) 2000-10-16 2003-04-08 Use of a wisp polypeptide for the preparation of medicaments for the treatment of mammalian cartilage cells or mammalian cartilage tissue damaged from a degenerative cartilagenous disorder or injury
IL200484A IL200484A (en) 2000-10-16 2009-08-19 Use of wisp polypeptides or biologically active fragment thereof for the preparation of medicaments for treatment of mammalian cartilage cells or tissue

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL155279A IL155279A (en) 2000-10-16 2003-04-08 Use of a wisp polypeptide for the preparation of medicaments for the treatment of mammalian cartilage cells or mammalian cartilage tissue damaged from a degenerative cartilagenous disorder or injury
IL200484A IL200484A (en) 2000-10-16 2009-08-19 Use of wisp polypeptides or biologically active fragment thereof for the preparation of medicaments for treatment of mammalian cartilage cells or tissue

Country Status (10)

Country Link
US (2) US7687460B2 (xx)
EP (3) EP1927659B1 (xx)
JP (1) JP4202128B2 (xx)
AT (3) ATE456655T1 (xx)
AU (2) AU2437702A (xx)
CA (1) CA2425145C (xx)
DE (2) DE60133301T2 (xx)
ES (3) ES2381935T3 (xx)
IL (3) IL155279A0 (xx)
WO (1) WO2002033085A2 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425145C (en) * 2000-10-16 2011-08-30 Genentech, Inc. Methods of treatment using wisp polypeptides
CA2536396A1 (en) * 2003-09-11 2005-03-24 Genentech, Inc. Methods of using wisp antagonists
SE0401069D0 (sv) 2004-04-26 2004-04-26 Anamar Medical Ab Use of Compounds for the Treatment of Diseases and Conditions
WO2007149328A1 (en) * 2006-06-20 2007-12-27 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
EP2147311A4 (en) * 2007-04-26 2010-08-11 Genera Istrazivanja D O O BLOOD BIOMARKER FOR BONE BREAKING AND BODILY INJURY
US8367621B2 (en) * 2008-01-18 2013-02-05 Sanford-Burnham Medical Research Institute Methods and compositions related to internalizing RGD peptides
EP2445536B1 (en) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Methods and compositions using peptides and proteins with c-terminal elements
KR20160015403A (ko) 2009-07-14 2016-02-12 더 스크립스 리서치 인스티튜트 중간엽 줄기 세포 분화
US20140037659A1 (en) * 2011-01-31 2014-02-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Snx9 as a novel biomarker for chronic inflammation and associated immunosuppresion and a new regulator of t cell receptor expression and function
JP6545959B2 (ja) 2012-02-11 2019-07-17 ジェネンテック， インコーポレイテッド Ｒスポンジン転位およびその使用方法
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
CA3011306A1 (en) * 2016-01-14 2017-07-20 Spinalcyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells
CN109152812A (zh) * 2016-06-02 2019-01-04 雀巢产品技术援助有限公司 用于治疗少肌症和肌肉损伤的方法
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
KR102167443B1 (ko) * 2019-03-25 2020-10-19 주식회사 카티프라임 체외 골관절염 모델 및 이를 이용한 골관절염 치료제 스크리닝 방법
CN111700881B (zh) * 2020-07-02 2021-05-18 四川大学 Wnt蛋白＼ZIF-8纳米复合体、其制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
WO1995017416A1 (en) 1993-12-22 1995-06-29 Merck & Co., Inc. Dna encoding the wnt-x growth factor
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
PT990000E (pt) 1996-11-08 2005-11-30 Human Genome Sciences Inc Factor 3 de crescimento do tecido conjuntivo
AU7980598A (en) * 1997-06-19 1999-01-04 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a growth factor-like protein (as amended)
US20020192209A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
DK1027437T3 (da) * 1997-10-29 2008-11-24 Genentech Inc Anvendelse af det WNT-1 inducerede udskilte polypeptid WISP-1
AU4411499A (en) * 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Connective tissue growth factor-4
KR100342045B1 (ko) * 1999-04-16 2002-06-27 김순택 2차전지
WO2001007085A1 (en) * 1999-07-23 2001-02-01 Case Western Reserve University Novel methods and reagents useful in the treatment of osteoarthritis
US20020063763A1 (en) * 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
GB9930768D0 (en) * 1999-12-29 2000-02-16 Pfizer Ltd Composition
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2425145C (en) * 2000-10-16 2011-08-30 Genentech, Inc. Methods of treatment using wisp polypeptides

Also Published As

Publication number Publication date
ATE389719T1 (de) 2008-04-15
JP4202128B2 (ja) 2008-12-24
WO2002033085A9 (en) 2002-07-25
CA2425145A1 (en) 2002-04-25
ATE544855T1 (de) 2012-02-15
IL200484A (en) 2012-05-31
ES2381935T3 (es) 2012-06-01
US20100093628A1 (en) 2010-04-15
EP2180053A2 (en) 2010-04-28
EP1326980B1 (en) 2008-03-19
ES2338492T3 (es) 2010-05-07
AU2002224377B2 (en) 2007-07-19
AU2002224377B8 (en) 2002-04-29
EP1927659B1 (en) 2010-01-27
AU2437702A (en) 2002-04-29
ATE456655T1 (de) 2010-02-15
DE60141236D1 (de) 2010-03-18
WO2002033085A2 (en) 2002-04-25
ES2304401T3 (es) 2008-10-16
DE60133301T2 (de) 2009-05-14
EP1927659A1 (en) 2008-06-04
IL155279A (en) 2011-05-31
US20050054563A1 (en) 2005-03-10
EP2180053A3 (en) 2010-11-10
US8138152B2 (en) 2012-03-20
WO2002033085A3 (en) 2003-04-17
DE60133301D1 (de) 2008-04-30
JP2004534720A (ja) 2004-11-18
CA2425145C (en) 2011-08-30
US7687460B2 (en) 2010-03-30
IL200484A0 (en) 2010-04-29
EP1326980A2 (en) 2003-07-16
EP2180053B1 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
IL200484A0 (en) Use of wisp polypeptides wisp for the preparation of medicaments
IL151408A0 (en) Use of insulin for the treatment of cartilagenous disorders
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
ATE338569T1 (de) Osteogene vorrichtungen und verfahren zu ihrer verwendung zur knochenreparatur
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
FR13C0062I1 (xx)
DE69433530D1 (de) Bmp-11 zusammensetzungen
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
WO2004019884A3 (en) Agents and methods for enhancing bone formation
PL331922A1 (en) Method of inhibiting fibrosis by means of an antagonist of somatotropin release inhibiting factor
ES2182902T3 (es) Sistema de reparacion de superficies de articulaciones.
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
DE69821793D1 (de) Neuronale verwendungen des bmp-11
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
IT1293305B1 (it) Sali di acidi difosfonici e loro impiego farmacologico nel trattamento dell'osteoporosi
ES2196349T3 (es) Uso de galanina para reparar lesiones en los nervios.
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
WO1997048368A3 (en) Naphthyridines which affect il-4 and g-csf
BR9709007A (pt) Uso de azaspirano substituìdo no tratamento da asma.